Novavax Stock Book Value Per Share
| NVAX Stock | USD 14.40 0.39 2.64% |
Novavax fundamentals help investors to digest information that contributes to Novavax's financial success or failures. It also enables traders to predict the movement of Novavax Stock. The fundamental analysis module provides a way to measure Novavax's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novavax stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (7.11) | (6.76) | |
| Tangible Book Value Per Share | (8.38) | (7.96) |
Novavax | Book Value Per Share |
Novavax Company Book Value Per Share Analysis
Novavax's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Novavax Book Value Per Share | (6.18) X |
Most of Novavax's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novavax is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Novavax Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Novavax is extremely important. It helps to project a fair market value of Novavax Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Novavax's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novavax's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novavax's interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Novavax Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Novavax is about -6.177 times. This is 263.35% higher than that of the Biotechnology sector and 97.52% lower than that of the Health Care industry. The book value per share for all United States stocks is 100.32% higher than that of the company.
Novavax Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novavax's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novavax could also be used in its relative valuation, which is a method of valuing Novavax by comparing valuation metrics of similar companies.Novavax is currently under evaluation in book value per share category among related companies.
Novavax ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novavax's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novavax's managers, analysts, and investors.Environmental | Governance | Social |
Novavax Fundamentals
| Return On Equity | -8.98 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.40) % | ||||
| Operating Margin | (1.48) % | ||||
| Current Valuation | 2.18 B | ||||
| Shares Outstanding | 147.3 M | ||||
| Shares Owned By Insiders | 4.97 % | ||||
| Shares Owned By Institutions | 57.26 % | ||||
| Number Of Shares Shorted | 44.93 M | ||||
| Price To Earning | (1.36) X | ||||
| Price To Book | 49.52 X | ||||
| Price To Sales | 0.61 X | ||||
| Revenue | 983.71 M | ||||
| Gross Profit | (156.04 M) | ||||
| EBITDA | (373.8 M) | ||||
| Net Income | (545.06 M) | ||||
| Cash And Equivalents | 1.28 B | ||||
| Cash Per Share | 16.31 X | ||||
| Total Debt | 280.63 M | ||||
| Debt To Equity | 8.24 % | ||||
| Current Ratio | 1.05 X | ||||
| Book Value Per Share | (6.18) X | ||||
| Cash Flow From Operations | (717.56 M) | ||||
| Short Ratio | 12.31 X | ||||
| Earnings Per Share | (3.05) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 1.54 K | ||||
| Beta | 1.62 | ||||
| Market Capitalization | 2.18 B | ||||
| Total Asset | 1.86 B | ||||
| Retained Earnings | (4.82 B) | ||||
| Working Capital | (491.25 M) | ||||
| Current Asset | 287.26 M | ||||
| Current Liabilities | 76.49 M | ||||
| Net Asset | 1.86 B |
About Novavax Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:Check out Novavax Piotroski F Score and Novavax Altman Z Score analysis. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.05) | Revenue Per Share 8.726 | Quarterly Revenue Growth 0.159 | Return On Assets (0.16) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.